Novelos Therapeutics Closes $3 Million Private Placement
"We are pleased with this financing, which will fund our current development programs into year end," said Harry Palmin, President and CEO of Novelos. "We continue to pursue our ex-US partnering initiative and other funding options. We recently demonstrated positive results with NOV-002 in two Phase 2 trials in ovarian and breast cancers, and our scientific progress was recognized in two peer reviewed publications. We expect detailed interim results of a Phase 2 breast cancer trial in December 2008, and we expect our pivotal, fully-enrolled, 840-patient Phase 3 lung cancer trial to conclude in mid-2009."
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and a chemopotentiator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer.
NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos.com